about lundbeck

Document technical information

Format pdf
Size 3.3 MB
First found Feb 4, 2016

Document content analysis

Category Also themed
Language
English
Type
not defined
Concepts

Medicine wikipedia, lookup

Generally Accepted Accounting Principles wikipedia, lookup

Alcoholism wikipedia, lookup

2010s wikipedia, lookup

Years in the future wikipedia, lookup

Copenhagen wikipedia, lookup

Escitalopram wikipedia, lookup

Lundbeck wikipedia, lookup

Persons

Organizations

Places

Transcript

lundbeck fast facts 2014
about
lundbeck
Fast facts 2014
1
lundbeck fast facts 2014
Kazuko Shiraishi
Depression
about lundbeck
Lundbeck is a global pharmaceutical company highly committed to
improving the quality of life of people suffering from brain diseases.
For this purpose, Lundbeck is engaged in the research, development,
production, marketing and sale of pharmaceuticals across the world.
The company’s products are targeted at diseases such as alcohol
dependence, depression, anxiety, psychotic diseases, epilepsy and
Huntington’s, Alzheimer’s and Parkinson’s diseases.
brain diseases
According to the World Health Organization, WHO, more than 700
million cases of brain diseases are reported every year. These are serious
and life-threatening diseases that affect the quality of life of the patients
as well as of their relatives. As these diseases also involve major socioeconomic costs, it is imperative for the general society that new and
innovative pharmaceuticals are developed. Over the past 50 years, new
pharmaceuticals have revolutionised the treatment options, but there
remains a large unmet need for new and innovative therapeutics.
research and development
Lundbeck is one of Denmark’s most research-intensive enterprises.
We employ more than 1,200 highly-trained specialists in our research
and development units. Each year, Lundbeck ploughs back around 20%
of its revenue into research and development of new pharmaceuticals to
improve treatment options for the millions of people around the world
suffering from brain diseases.
products
Lundbeck markets a number of different pharmaceuticals for the
treatment of brain diseases. The most recently launched compounds
include: Brintellix® (depression), Cipralex/Lexapro® (depression), Abilify
Maintena® (schizophrenia), Selincro® (alcohol dependence), Azilect®
(Parkinson’s disease), Xenazine® (chorea associated with Huntington’s
disease), Sabril® (epilepsy) and Onfi® (Lennox-Gastaut syndrome).
2
lundbeck fast facts 2014
management
Lundbeck’s Executive Management consists of three members,
headed by Ulf Wiinberg, President and CEO.
CEO
ulf wiinberg
R&D
Finance & IT
anders gersel pedersen
anders götzsche
Corporate Business Development,
People & Strategy
International Markets
Legal Affairs
R&D Project Strategy
& Portfolio Management
Strategic Marketing
Supply Operations
& Engineering
jacob tolstrup
ole chrintz
mette carlstedt
allan wehnert
andreas eggert
lars bang
key figures
Lundbeck employs approximately 6,000 people worldwide, 2,000 of
whom are based in Denmark. We have employees in 57 countries, and
our products are registered in approximately 100 countries. We have
production facilities in China, Denmark, France and Italy and research
centres in Denmark, China and the United States. Lundbeck generated
revenue of approximately DKK 15.3 billion in 2013.
revenue and profit, 2013
employees worldwide, end 2013
20,000
7,000
6,000
16,000
5,000
12,000
4,000
8,000
3,000
2,000
4,000
1,000
0
0
Net profit
2010
2011
Profit from operations
2012
2013
2010
Revenue
USA
2011
Europe (excl. Denmark)
2012
Denmark
2013
International Markets
3
lundbeck fast facts 2014
history
Lundbeck was founded by Hans Lundbeck as a trading company in 1915.
Since then the company has evolved and grown dramatically. Today we
are among the biggest Danish companies, and focus solely on developing
pharmaceuticals for the treatment of brain diseases.
market data
In 2012, 46% of our revenue derived from Europe, 17% from the USA
and 27% from the International Markets region.
revenue 2013
10% (-22%)
27% (+8%)
46% (-9%)
Europe
USA
International Markets
Other revenue
17% (+22%)
ownership
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock
Exchange. The Lundbeck Foundation owns about 70% of the shares in
Lundbeck, while the remaining 30% are traded on the stock exchange.
The Foundation annually distributes around DDK 400-500m in grants for
various types of research.
contact details
H. Lundbeck A/S
Ottiliavej 9
2500 Valby
Denmark
Corporate Communication
Tel. +45 36 30 13 11
[email protected]
www.lundbeck.com
4

Similar documents

×

Report this document